This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lamy, S. Articles by Béliveau, R. Search for Related Content PubMed PubMed Citation Articles by Lamy, S. Articles by Béliveau, R.

Green Tea Catechins Inhibit Vascular Endothelial Growth Factor Receptor Phosphorylation¹

Laboratoire de Médecine Moléculaire, Centre de Cancérologie Charles-Bruneau, Hôpital Ste-Justine et Université du Québec à Montréal, Montréal, Québec H3C 3P8, Canada

	ABSTRACT

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Vascular endothelial growth factor (VEGF) receptors (VEGFR) play a major role in tumor angiogenesis and, thus, represent attractive targets for the development of novel anticancer therapeutics. In this work, we report that green tea catechins are novel inhibitors of VEGFR-2 activity. Physiological concentrations (0.01–1 µM) of epigallocatechin-3 gallate, catechin-3 gallate, and, to a lesser extent, epicatechin-3 gallate induce a rapid and potent inhibition of VEGF-dependent tyrosine phosphorylation of VEGFR-2. The inhibition of VEGFR-2 by epigallocatechin-3 gallate was similar to that induced by Semaxanib (SU5416), a specific VEGFR-2 inhibitor. The inhibition of VEGFR-2 activity by the catechins displayed positive correlation with the suppression of in vitro angiogenesis. These observations suggest that the anticancer properties of green tea extracts may be related to their inhibition of VEGF-dependent angiogenesis.

	Introduction

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
There is increasing evidence supporting the central role of angiogenesis in tumor growth and metastasis (1) . As a consequence, tremendous efforts have been made to identify antiangiogenic molecules with antitumor properties (2) , leading to the development of a variety of molecules targeting critical aspects of angiogenesis such as cell adhesion, degradation of the extracellular matrix, and stimulation of endothelial cells by angiogenic cytokines (3) . VEGF³ is an endothelial cell-specific mitogen that is often associated with tumor-induced angiogenesis. At the endothelial cell surface, VEGF binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR; Flk-1 in mice), the latter being responsible for most of the mitogenic and chemotactic effects of VEGF (4) . For this reason, intense research has focused on the development of anti-VEGF and anti-VEGFR-2 compounds to inhibit angiogenesis (5) .

Green tea, the beverage made from the unfermented leaves of Camellia sinensis, is one of the most ancient and widely consumed beverages in the world. Green tea polyphenols have demonstrated significant antioxidant, anticarcinogenic, antimutagenic, anti-inflammatory, and antimicrobial properties (6) . On the basis of a large body of evidence, it has become clear that green tea is an effective chemopreventive agent for many types of cancer in animal tumor models, including those involving tumors of the skin, breast, lung, liver, esophagus, forestomach, small intestine, pancreas, and colon (7) .

The chemical components found in green tea consist mainly of polyphenols (flavanols), commonly known as catechins. The major catechins in green tea are EC, ECG, EGC, and EGCG (8) . Most of the biological effects of green tea appear to be mediated by its major polyphenolic constituent, EGCG. The anticarcinogenic properties of green tea polyphenols are likely to be the result of many biological responses (7) , including the inhibition of urokinase activity, an enzyme crucial for cancer growth (9) . However, the concentrations of EGCG used in most of these studies seem too high to account for the anticancer activity associated with green tea, based on the levels measured in human blood and serum after oral consumption (10) . Green tea and one of its components, EGCG, were shown recently to prevent the growth of new blood vessels in a chick CAM assay (11) , suggesting the presence of antiangiogenic molecules within green tea. In this work, we present evidence that these antiangiogenic effects of green tea are correlated with potent inhibitory effects of a number of green tea catechins on VEGFR-2 activity.

	Materials and Methods

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Materials.
DMEM low glucose, penicillin/streptomycin, and endothelial basal medium MCDB 131 were obtained from Life Technologies, Inc. (Burlington, Ontario, Canada). Epidermal growth factor and Matrigel basement membrane matrix were obtained from Becton Dickinson Labware (Bedford, MA). Bovine calf serum and fetal bovine serum were obtained from Hyclone Laboratories (Logan, UT) and Medicorp (Montreal, Quebec, Canada), respectively. Hydrocortisone and (+)C, (-)EC, (-)CG, (-)ECG, and (-)EGC catechins were purchased from Sigma Chemical Co. (St. Louis, MO). (-)EGCG catechin was obtained from ICN Biomedicals, Inc. (Aurora, OH). Human recombinant VEGF was obtained from R&D Systems, Inc. (Minneapolis, MN). SU5416 was from Calbiochem (La Jolla, CA). Electrophoresis reagents were purchased from Bio-Rad (Mississauga, Ontario, Canada). Protein A-Sepharose and protein G-Sepharose were obtained from Amersham Pharmacia Biotech (Baie d’Urfe, Quebec, Canada). The anti-VEGFR-1 and -VEGFR-2 polyclonal antibodies, and the anti-Tyr(P) PY99 monoclonal antibody were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antimouse IgG horseradish peroxidase-linked whole antibody was from Jackson ImmunoResearch Laboratories (West Grove, PA) and Western Blot Cheluminescence Reagents Plus were from NEN Life Science Products, Inc. (Boston, MA).

Cell Culture.
BAECs were purchased from Clonetics (San Diego, CA) and maintained in DMEM low glucose containing 10% heat-inactivated bovine calf serum, 100 units/ml penicillin, and 100 µg/ml streptomycin. The cells were grown, serum-starved, and stimulated with 1 nM of VEGF as described previously (12) . HMEC-1 was obtained from the Centers for Disease Control and Prevention (Atlanta, GA) and maintained in MCDB 131 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, 10 ng/ml epidermal growth factor, and 1 mg/ml hydrocortisone. All of the cells were cultured at 37°C under a humidified atmosphere containing 5% CO₂.

Immunoprecipitation and Immunoblotting Procedures.
For immunoblotting analysis of VEGFRs after immunoprecipitation, cells were lysed with ice-cold lysis buffer [150 mM NaCl, 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 0.5% NP40, and 1% Triton X-100] containing 1 mM Na₃VO₄. After each treatment, equal amounts of protein (100 µg) were precleared by incubation with a mixture of protein A/protein G-Sepharose beads for 1 h at 4°C. After removal of the Sepharose beads by low-speed centrifugation, the supernatants were transferred to fresh tubes. Lysate supernatants were incubated in lysis buffer overnight at 4°C in the presence of 2 µg/ml of specific antibodies. Immunocomplexes were collected by incubating lysates with 25 µl of protein A-Sepharose beads (50% suspension) for another 2 h at 4°C. Immunoprecipitates were then washed three times with lysis buffer and once with PBS (pH 7.4) containing 1 mM Na₃VO₄. The proteins were extracted with 2-fold concentrated Laemmli sample buffer [125 mM Tris-HCl (pH 6.8), 20% glycerol, 4% SDS, 10% ß-mercaptoethanol, and 0.00125% bromphenol blue], boiled for 4 min, separated on 7.5% SDS-PAGE, and analyzed by Western blotting as described previously (12) .

In Vitro Kinase Assay.
Confluent BAEC were serum starved for 24 h, and the cells were then stimulated with VEGF and lysed as described above. Precleared cell lysates (450 µg proteins) were incubated overnight with anti-VEGFR-2 antibodies, and the resulting immune complexes were collected with protein A-Sepharose beads and washed as described above. The washed beads were incubated for 1 h on ice in 15 µl of kinase buffer [100 mM Tris-HCl (pH 7.0), 0.2% ß-mercaptoethanol, 20 mM MgCl₂, and 0.2 mM Na₃VO₄] containing the specific catechin. The kinase reaction was initiated by the addition of 5 µCi of [-³²P]ATP (ICN Biochemicals) into a final volume of 20 µl and incubated at 30°C for 15 min. The reaction was stopped by adding Laemmli sampler buffer, and proteins were separated by electrophoresis on 7.5% SDS gels. The resulting gels were stained for 30 min in 0.1% (w/v) Coomassie Blue R-250 in 30% methanol and 10% acetic acid, and destained in the same solution without the Coomassie Blue dye. The gels were then washed extensively in this solution and exposed to Fuji X-ray film.

Matrigel Endothelial Cell Tube Formation Assays.
Matrigel (12.5 mg/ml) was thawed at 4°C, and 50 µl were quickly added to each well of a 96-well plate and allowed to solidify for 10 min at 37°C. Once solid, the wells were incubated for 30 min with HMEC-1 (25,000 cells/well). After adhesion of the cells, the medium was removed and replaced by fresh medium supplemented (or not) with 50 µM of C, ECG, EGCG, or SU5416, and incubated at 37°C for 18 h. The tubes of growth were visualized with an inverted Nikon/TMS microscope at a magnification of x4, and the length of the capillary network was quantified with a map scale calculator.

	Results

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Effect of Green Tea Polyphenols on VEGF-induced Tyrosine Phosphorylation of VEGFRs.
To better understand the inhibitory action of green tea polyphenols on the induction of in vitro angiogenesis, we examined their effect on the function of the most potent angiogenic factor, VEGF. Strong evidence shows that blocking VEGFR-2 activity limits the ability of most tumors to stimulate the formation of blood vessels (13) . Thus, we examined whether the different polyphenols from green tea could have an effect on VEGF-induced tyrosine phosphorylation of VEGFR-2. Quiescent BAEC were incubated in serum-free medium in the presence or absence of 25 µM of each catechin (C, EC, ECG, CG, EGC, and EGCG) for 24 h. The medium was then replaced with fresh serum-free medium without catechins, and the cells were stimulated with 1 nM of recombinant VEGF for 1 min. The phosphorylation state of the VEGFR-2 was assessed by immunoprecipitation of the receptor followed by Tyr(P) immunodetection. Under these conditions, VEGF caused a marked increase in the tyrosine phosphorylation state of VEGFR-2 in untreated BAEC (Fig. 1A , top panel). The increase in tyrosine-phosphorylated VEGFR-2 was completely inhibited in BAEC by three of the catechins, CG, ECG, and EGCG. The total amount of VEGFR-2 in each sample of cells was unaffected by the catechins (Fig. 1A , bottom panel). Furthermore, the treatment of the cells with catechins at 25 µM did not induce significant cell death nor apoptosis (data not shown). These results suggest that CG, ECG, and EGCG are potent inhibitors of VEGF-induced tyrosine phosphorylation of VEGFR-2. We have shown previously that the phosphorylation of another VEGFR, VEGFR-1, in BAEC was stimulated to a much lesser extent by VEGF compared with that of VEGFR-2 (12) . Thus, we examined the inhibitory effect of the most potent inhibitor catechin, EGCG, on the tyrosine phosphorylation levels of VEGFR-1. As shown in Fig. 1B , addition of EGCG completely inhibits VEGF-dependent phosphorylation of VEGFR-1.

View larger version (26K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. Effect of VEGF on the tyrosine phosphorylation of VEGFRs in BAEC treated with green tea catechins. A, quiescent cells were incubated in serum-free medium in the presence or absence of 25 µM of each indicated catechin for 24 h. The medium was replaced with serum-free medium without catechins, and BAEC were stimulated with 1 nM of recombinant VEGF for 1 min. The extent of tyrosine phosphorylation was determined by immunoprecipitation as described in "Materials and Methods" (top panel). The effects of the treatments on the amount of VEGFR-2 were assessed by Western blotting using anti-VEGFR-2 antibodies (bottom panel). B, BAEC were pretreated with 25 µM of EGCG for 24 h and then stimulated with VEGF. Lysates were subjected to immunoprecipitation with anti-VEGFR-1 antibody, and the Tyr(P) content of the receptor was visualized by immunoblotting with the anti-Tyr(P) antibody. C, BAECs were pretreated with different concentrations of CG, ECG, or EGCG for 24 h and then stimulated with VEGF. The levels of tyrosine-phosphorylated VEGFR-2 were monitored by immunoprecipitation with anti-VEFGR-2 and immunoblotting with anti-Tyr(P) monoclonal antibody. Laser densitometric analysis of the bands was performed to quantify the effect of VEGF on tyrosine phosphorylation of VEGFR-2 in BAEC after treatment with various concentrations of ECG (), CG (), and EGCG ().

Time Course of the Inhibitory Effect of Green Tea Polyphenols on the Tyrosine Phosphorylation of VEGFR-2.
We conducted time course studies to characterize the inhibition by the specific catechin compounds. Serum-starved quiescent BAECs were incubated with a catechin (50 µM) for varying lengths of time and then stimulated with VEGF. As shown in Fig. 2A , the tyrosine phosphorylation of VEGFR-2 by VEGF was rapidly inhibited by CG and EGCG (<3 h), unlike ECG, which had produced no effect during the 5-h experiment. Moreover, the inhibitory effect of EGCG was extremely rapid, being observed after as little as 30 min. The rapid kinetics of EGCG inhibitory activity prompted us to more precisely examine the time course between 1 and 30 min. The results show that the inhibition by EGCG was time-dependent and was already complete at 20 min where a return to a basal level of phosphorylation was observed (Fig. 2B) . To additionally explain the mechanisms involved in the inhibitory action of EGCG, we compared its effect with that of a potent and selective synthetic inhibitor of VEGFR-2, SU5416 (14) . For both of these two molecules, significant inhibition occurred at 10 µM for 30 min of incubation with the cells (Fig. 2C) . Interestingly, VEGFR-2 was more sensitive to the inhibitory effect of EGCG than to that of SU5416.

View larger version (38K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. Time- and dose-dependent inhibition of VEGF-induced tyrosine phosphorylation of VEGFR-2 by green tea catechins. Quiescent BAECs were incubated in serum-free medium in the presence or absence of 50 µM of CG, ECG, or EGCG for the indicated times (A), with EGCG (50 µM) for 1, 5, 10, 20, and 30 min (B), with 1, 10, 25, and 50 µM of EGCG or SU5416 for 30 min (C), or with catalase (1000 units) and EGCG (50 µM) for 1 h (D). After 24 h of serum deprivation, BAECs were incubated in serum-free medium containing 1 nM of VEGF for 1 min. The resulting lysates were incubated with polyclonal antibodies raised against VEGFR-2, and the immune complexes were subjected to SDS-PAGE followed by immunoblotting with anti-Tyr(P) monoclonal antibody. Densitometric measurement was used to quantify the levels of tyrosine-phosphorylated VEGFR-2 (C). , EGCG treatment, and , SU5416 treatment.

Effect of Green Tea Polyphenols on the Tyrosine Kinase Activity of VEGFR-2.
To determine whether the inhibition of tyrosine phosphorylation of VEGFR-2 by the catechins resulted in a diminution of its kinase activity, anti-VEGFR-2 immunoprecipitates from treated cells were subjected to in vitro kinase assays. A concentration of 10 µM of EGCG was used in this study, because at this concentration EGCG inhibited the VEGF-dependent kinase activity of VEGFR-2 but did not affect its basal kinase activity (data not shown). Moreover, we used C catechin as a control, because it had no effect on the tyrosine phosphorylation of VEGFR-2. As shown in Fig. 3 , immunoprecipitates from CG- and EGCG-treated cells showed a diminution in the radiolabeling of the receptor, indicating that both catechins reduced the kinase activity of the receptor at 10 µM compared with ECG, which shows no significant effect. At 50 µM, the tyrosine kinase activity of VEGFR-2 was also reduced by ECG (data not shown). These data confirm that CG and EGCG are the most potent catechin inhibitors and that ECG inhibits VEGFR-2 less effectively. Overall, these results suggest a potential direct interaction of the catechins with the catalytic activity associated with VEGFR-2.

View larger version (70K): [in this window] [in a new window] [Download PPT slide]   Fig. 3. Effect of CG, ECG, and EGCG on the tyrosine kinase activity of VEGFR-2. Anti-VEGFR-2 immunoprecipitates from treated cells (+)-C, (-)-CG, (-)-ECG, and (-)-EGCG were subjected to an in vitro kinase assay as described in "Materials and Methods." Samples were separated by SDS-PAGE followed by autoradiography.

View larger version (78K): [in this window] [in a new window] [Download PPT slide]   Fig. 4. Effect of green tea catechins and SU5416 compound on the Matrigel-induced tube formation of HMEC-1. Representative microscopy photographs of HMEC-1 cultured for 18 h on Matrigel in the presence or absence of 50 µM of the indicated compounds are illustrated. The length of the capillary network was quantified as described in "Materials and Methods."

	Discussion

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

In contrast to most studies on green tea catechins, which have used rather high concentrations of these compounds, we observed that low physiological concentrations of EGCG were sufficient to significantly inhibit VEGFR-2 activity. Indeed, a 50% inhibition of VEGF-dependent tyrosine phosphorylation of VEGFR-2 could be observed at a concentration of 0.01 µM EGCG, 10-fold less than its plasma concentration in tea drinkers (11 , 20 , 21) . We also observed that, under our experimental conditions, EGCG was as potent as SU5416 in inhibiting VEGFR-2 tyrosine phosphorylation. In in vitro Matrigel assays, EGCG was even more inhibitory than was SU5416, possibly reflecting its activity against other components of the angiogenesis process such as matrix metalloproteinases (22) . Because SU5416 is known to inhibit angiogenesis both in vitro and in vivo, these results strongly support the concept that EGCG represents a potent angiogenesis inhibitor.

RTKs (also known as growth factor receptors) play an important role in many cellular processes such as proliferation, differentiation, morphogenesis, and angiogenesis (23) . Disturbances in the expression of growth factors, their cognate RTKs, or constituents of their downstream signaling pathways are commonly associated with many types of cancer and other nonmalignant proliferative diseases (23, 24, 25) . Therefore, the targeting of RTKs to inhibit tumor growth has received considerable attention in recent years (24) . EGCG has been demonstrated previously to inhibit the protein tyrosine kinase activities of the PDGFR (21) and fibroblast growth factor receptor (26) . We extend these observations by showing that EGCG also interferes with the activity of VEGFR-2 at the endothelial cell level. It seems that EGCG is more active against VEGFR than PDGFR, because the reported inhibitory effect on tyrosine phosphorylation of PDGFR-ß only appeared at 50 µM (21) as compared with that of VEGFR-2 (0.01 µM) observed in our study. Moreover, it is possible that, like SU5416, EGCG could be a potent, competitive (in regard to ATP) inhibitor of the tyrosine kinase activity of VEGFR-2, thereby inhibiting its tyrosine phosphorylation. These results suggest that EGCG may act as a multifunctional anticancer agent through its inhibitory effect on several aspects of both tumor growth and tumor angiogenesis. Our findings may be helpful in designing future strategies for the development of green tea as a practical chemopreventive agent and a potential clinical therapy in combination with current anticancer drugs.

	ACKNOWLEDGMENTS

 
We thank Dr. Edwin Ades and Francisco J. Candal of Centers for Disease Control and Prevention, and Dr. Thomas Lawley of Emory University for HMEC-1. We also thank Dr. Borhane Annabi of Université du Québec à Montréal for his critical reading of the manuscript.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by Grants from the Fondation Charles-Bruneau, Hôpital Ste-Justine, Québec, Canada, and from the Cancer Research Society of Canada.

² To whom requests for reprints should be addressed, at Laboratoire de Médecine Moléculaire, Center de Recherche de l’Hôpital Ste-Justine, 3175 Chemin Côte-Ste-Catherine, Montréal, Québec H3T 1C5, Canada. Phone: (514) 345-4931, extension 2366; Fax: (514) 345-2359; E-mail: molmed{at}justine.umontreal.ca

³ The abbreviations used are: VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; C, catechin; CG, catechin-3 gallate; EC, epicatechin; ECG, epicatechin-3 gallate; EGC, epigallocatechin; EGCG, epigallocatechin-3 gallate; Tyr(P), phosphotyrosine; CAM, chorioallantoic membrane; BAEC, bovine aortic endothelial cell; HMEC, human microvascular endothelial cell; RTK, receptor tyrosine kinase; PDGFR, platelet-derived growth factor receptor; Flt-1, fms-like tyrosine kinase receptor (or VEGFR-1); KDR, kinase insert domain-containing receptor (or VEGFR-2).

Received 9/18/01. Accepted 11/29/01.

	REFERENCES

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 

1. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.[Medline]
2. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist, 5: 20-27, 2000.[Abstract/Free Full Text]
3. Liekens S., De Clercq E., Neyts J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol., 61: 253-270, 2001.[Medline]
4. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol., 280: C1358-C1366, 2001.[Abstract/Free Full Text]
5. Schlaeppi J. M., Wood J. M. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev., 18: 473-481, 1999.[Medline]
6. Fujiki H. Two stages of cancer prevention with green tea. J. Cancer Res. Clin. Oncol., 125: 589-597, 1999.[Medline]
7. Mukhtar H., Ahmad N. Green tea in chemoprevention of cancer. Toxicol. Sci., 52: 111-117, 1999.[Abstract/Free Full Text]
8. Chu D-C., Juneja L. R. General chemical composition of green tea and its infusion Yamamoto T. Juneja L. R. Chu D-C. Kim M. eds. . Chemistry and Applications of Green Tea, : 13-22, CRC Press New York 1997.
9. Jankun J., Selman S. H., Swiercz R., Skrzypczak-Jankun E. Why drinking green tea could prevent cancer. Nature (Lond.), 387: 561 1997.[Medline]
10. Webb T. Green tea experiments in lab, clinic yields mixed results. J. Natl. Cancer Inst. (Bethesda), 92: 1038-1039, 2000.[Free Full Text]
11. Cao Y., Cao R. Angiogenesis inhibited by drinking tea. Nature (Lond.), 398: 381 1999.[Medline]
12. Gingras D., Lamy S., Béliveau R. Tyrosine phosphorylation of the vascular endothelial growth factor receptor-2 (VEGFR-2) is modulated by Rho proteins. Biochem. J., 348: 273-280, 2000.
13. Shaheen R. M., Davis D. W., Liu W., Zebrowski B. K., Wilson M. R., Bucana C. D., McConkey D. J., McMahon G., Ellis L. M. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer, liver metastasis, and induces tumor and endothelial cell apoptosis. Cancer Res., 59: 5412-5416, 1999.[Abstract/Free Full Text]
14. Mendel D. B., Laird A. D., Smolich B. D., Blake R. A., Liang C., Hannah A. L., Shaheen R. M., Ellis L. M., Weitman S., Shawver L. K., Cherrington J. M. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des., 15: 29-41, 2000.[Medline]
15. Long L. H., Clement M. V., Halliwell B. Artifacts in cell culture: rapid generation of hydrogen peroxide on addition of (-)-epigallocatechin, (-)-epigallocatechin gallate, (+)-catechin, and quercetin to commonly used cell culture media. Biochem. Biophys. Res. Commun., 273: 50-53, 2000.[Medline]
16. Yang G-Y., Liao J., Li C., Chung J., Yurkow E. J., Ho C-T., Yang C. S. Effect of black and green tea polyphenols on c-jun phosphorylation and H₂O₂ production in transformed and non-transformed human bronchial cell lines: possible mechanisms of cell growth inhibition and apoptosis induction. Carcinogenesis (Lond.), 21: 2035-2039, 2000.[Abstract/Free Full Text]
17. Baatout S., Cheta N. Matrigel: a useful tool to study endothelial differentiation. Rom. J. Intern. Med., 34: 263-269, 1996.[Medline]
18. Jung Y. D., Kim M. S., Shin B. A., Chay K. O., Ahn B. W., Liu W., Bucana C. D., Gallick G. E., Ellis L. M. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br. J. Cancer, 84: 844-850, 2001.[Medline]
19. Nam S., Smith D. M., Dou Q. P. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem., 276: 13322-13330, 2001.[Abstract/Free Full Text]
20. Yang C. S., Chen L., Lee M. J., Balentine D., Kuo M. C., Schantz S. P. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol. Biomark. Prev., 7: 351-354, 1998.[Abstract]
21. Sachinidis A., Seul C., Seewald S., Ahn H-Y., Ko Y., Vetter H. Green tea compounds inhibit tyrosine phosphorylation of PDGF ß-receptor and transformation of A172 human glioblastoma. FEBS Lett., 47: 51-55, 2000.
22. Demeule M., Brossard M., Pagé M., Gingras D., Béliveau R. Matrix metalloproteinase inhibition by green tea catechins. Biochim. Biophys. Acta, 1478: 51-60, 2000.[Medline]
23. Shawver L. K., Lipson K. E., Fong T. A. T., McMahon G., Plowman G. D., Strawn L. M. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discov. Today, 2: 50-63, 1997.
24. Levitzki A., Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science (Wash. DC), 267: 1782-1788, 1995.[Abstract/Free Full Text]
25. Hunter T. Oncoprotein networks. Cell, 88: 333-346, 1997.[Medline]
26. Liang Y. C., Lin-Shiau S. Y., Chen C. F., Lin J. K. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J. Cell. Biochem., 67: 55-65, 1997.[Medline]

This article has been cited by other articles:

				A. S. Tsao, D. Liu, J. Martin, X.-m. Tang, J. J. Lee, A. K. El-Naggar, I. Wistuba, K. S. Culotta, L. Mao, A. Gillenwater, et al. Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions Cancer Prevention Research, November 1, 2009; 2(11): 931 - 941. [Abstract] [Full Text] [PDF]

				T. D. Shanafelt, T. G. Call, C. S. Zent, B. LaPlant, D. A. Bowen, M. Roos, C. R. Secreto, A. K. Ghosh, B. F. Kabat, M.-J. Lee, et al. Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia J. Clin. Oncol., August 10, 2009; 27(23): 3808 - 3814. [Abstract] [Full Text] [PDF]

				D. Labbe, M. Provencal, S. Lamy, D. Boivin, D. Gingras, and R. Beliveau The Flavonols Quercetin, Kaempferol, and Myricetin Inhibit Hepatocyte Growth Factor-Induced Medulloblastoma Cell Migration J. Nutr., April 1, 2009; 139(4): 646 - 652. [Abstract] [Full Text] [PDF]

				H. Xu, W.T. Lui, C.Y. Chu, P.S. Ng, C.C. Wang, and M.S. Rogers Anti-angiogenic effects of green tea catechin on an experimental endometriosis mouse model Hum. Reprod., March 1, 2009; 24(3): 608 - 618. [Abstract] [Full Text] [PDF]

				M. W. Laschke, C. Schwender, C. Scheuer, B. Vollmar, and M. D. Menger Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo Hum. Reprod., October 1, 2008; 23(10): 2308 - 2318. [Abstract] [Full Text] [PDF]

				R. Beliveau and D. Gingras Role of nutrition in preventing cancer Can Fam Physician, November 1, 2007; 53(11): 1905 - 1911. [Abstract] [Full Text] [PDF]

				L. Lamalice, F. Houle, and J. Huot Phosphorylation of Tyr1214 within VEGFR-2 Triggers the Recruitment of Nck and Activation of Fyn Leading to SAPK2/p38 Activation and Endothelial Cell Migration in Response to VEGF J. Biol. Chem., November 10, 2006; 281(45): 34009 - 34020. [Abstract] [Full Text] [PDF]

				R. P Singh and R. Agarwal Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778. [Abstract] [Full Text] [PDF]

				M. F. McCarty and K. I. Block Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy Integr Cancer Ther, September 1, 2006; 5(3): 252 - 268. [Abstract] [PDF]

				C. Guichard, E. Pedruzzi, M. Fay, J.-C. Marie, F. Braut-Boucher, F. Daniel, A. Grodet, M.-A. Gougerot-Pocidalo, E. Chastre, L. Kotelevets, et al. Dihydroxyphenylethanol induces apoptosis by activating serine/threonine protein phosphatase PP2A and promotes the endoplasmic reticulum stress response in human colon carcinoma cells Carcinogenesis, September 1, 2006; 27(9): 1812 - 1827. [Abstract] [Full Text] [PDF]

				M. F. McCarty and K. I. Block Toward a Core Nutraceutical Program for Cancer Management Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171. [Abstract] [PDF]

				F. Spinella, L. Rosano, V. Di Castro, S. Decandia, A. Albini, M. R. Nicotra, P. G. Natali, and A. Bagnato Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol. Cancer Ther., June 1, 2006; 5(6): 1483 - 1492. [Abstract] [Full Text] [PDF]

				S. Lamy, M. Blanchette, J. Michaud-Levesque, R. Lafleur, Y. Durocher, A. Moghrabi, S. Barrette, D. Gingras, and R. Beliveau Delphinidin, a dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 phosphorylation Carcinogenesis, May 1, 2006; 27(5): 989 - 996. [Abstract] [Full Text] [PDF]

				Q. Zhang, X. Tang, Q. Lu, Z. Zhang, J. Rao, and A. D. Le Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1{alpha} protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells Mol. Cancer Ther., May 1, 2006; 5(5): 1227 - 1238. [Abstract] [Full Text] [PDF]

				M. F. McCarty and K. I. Block Multifocal Angiostatic Therapy: An Update Integr Cancer Ther, December 1, 2005; 4(4): 301 - 314. [Abstract] [PDF]

				P. S. Haddad, G. A. Azar, S. Groom, and M. Boivin Natural Health Products, Modulation of Immune Function and Prevention of Chronic Diseases Evid. Based Complement. Altern. Med., December 1, 2005; 2(4): 513 - 520. [Abstract] [Full Text] [PDF]

				J. El Bedoui, M.-H. Oak, P. Anglard, and V. B. Schini-Kerth Catechins prevent vascular smooth muscle cell invasion by inhibiting MT1-MMP activity and MMP-2 expression Cardiovasc Res, August 1, 2005; 67(2): 317 - 325. [Abstract] [Full Text] [PDF]

				L. Labrecque, S. Lamy, A. Chapus, S. Mihoubi, Y. Durocher, B. Cass, M. W. Bojanowski, D. Gingras, and R. Beliveau Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound Carcinogenesis, April 1, 2005; 26(4): 821 - 826. [Abstract] [Full Text] [PDF]

				S. J. Baek, J.-S. Kim, F. R. Jackson, T. E. Eling, M. F. McEntee, and S.-H. Lee Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells Carcinogenesis, December 1, 2004; 25(12): 2425 - 2432. [Abstract] [Full Text] [PDF]

				Y. K. Lee, N. D. Bone, A. K. Strege, T. D. Shanafelt, D. F. Jelinek, and N. E. Kay VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia Blood, August 1, 2004; 104(3): 788 - 794. [Abstract] [Full Text] [PDF]

				G. Fassina, R. Vene, M. Morini, S. Minghelli, R. Benelli, D. M. Noonan, and A. Albini Mechanisms of Inhibition of Tumor Angiogenesis and Vascular Tumor Growth by Epigallocatechin-3-Gallate Clin. Cancer Res., July 15, 2004; 10(14): 4865 - 4873. [Abstract] [Full Text] [PDF]

				B. Annabi, S. Thibeault, R. Moumdjian, and R. Beliveau Hyaluronan Cell Surface Binding Is Induced by Type I Collagen and Regulated by Caveolae in Glioma Cells J. Biol. Chem., May 21, 2004; 279(21): 21888 - 21896. [Abstract] [Full Text] [PDF]

				T. P. Kenny, C. L. Keen, P. Jones, H.-J. Kung, H. H. Schmitz, and M. E. Gershwin Pentameric Procyanidins Isolated from Theobroma cacao Seeds Selectively Downregulate ErbB2 in Human Aortic Endothelial Cells Experimental Biology and Medicine, March 1, 2004; 229(3): 255 - 263. [Abstract] [Full Text] [PDF]

				M. Masuda, M. Suzui, J. T. E. Lim, and I. B. Weinstein Epigallocatechin-3-gallate Inhibits Activation of HER-2/neu and Downstream Signaling Pathways in Human Head and Neck and Breast Carcinoma Cells Clin. Cancer Res., August 1, 2003; 9(9): 3486 - 3491. [Abstract] [Full Text] [PDF]

				J. Hong, H. Lu, X. Meng, J.-H. Ryu, Y. Hara, and C. S. Yang Stability, Cellular Uptake, Biotransformation, and Efflux of Tea Polyphenol (-)-Epigallocatechin-3-Gallate in HT-29 Human Colon Adenocarcinoma Cells Cancer Res., December 15, 2002; 62(24): 7241 - 7246. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lamy, S. Articles by Béliveau, R. Search for Related Content PubMed PubMed Citation Articles by Lamy, S. Articles by Béliveau, R.